LB Pharma accelerates Phase 3 NOVA-2 topline to H1 2027; cash runway into Q2 2029

LB PHARMACEUTICALS INC

Topline results from Phase 3 NOVA-2 trial of LB-102 in schizophrenia now expected in first half of 2027, ahead of prior guidance.
Pre-NDA meeting with FDA scheduled for second half of 2027.
Cash runway expected to fund operations into Q2 2029 through multiple clinical readouts.
Phase 2 ILLUMINATE-1 trial in bipolar depression topline expected in Q1 2028.
Phase 2 trial of LB-102 in adjunctive MDD topline expected in first half of 2029.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.